A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

por Sharman, Jeffrey P., Biondo, Juliana M. L., Boyer, Michelle, Fischer, Kirsten, Hallek, Michael, Jiang, Dingfeng, Kater, Arnon P., Porro Lurà, Michele, Wierda, William G.
Publicado 2022

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase...

por Mato, Anthony R., Sharman, Jeff P., Biondo, Juliana M.L., Wu, Mei, Mun, Yong, Kim, Su Y., Humphrey, Kathryn, Boyer, Michelle, Zhu, Qian, Seymour, John F.
Publicado 2020

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

por Handunnetti, Sasanka, Anderson, Mary Ann, Roberts, Andrew W., Davids, Matthew S., Ma, Shuo, Boyer, Michelle, Arzt, Jennifer, Masud, Abdullah Al, Popovic, Relja, Jacobson, Amanda, Kim, Su Y., Seymour, John F.
Publicado 2021

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

por Davids, Matthew S., Roberts, Andrew W., Kenkre, Vaishalee P., Wierda, William G., Kumar, Abhijeet, Kipps, Thomas J., Boyer, Michelle, Salem, Ahmed Hamed, Pesko, John C., Arzt, Jennifer A., Mantas, Margaret, Kim, Su Y., Seymour, John F.
Publicado 2021

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CL...

por Kater, Arnon, Harrup, Rosemary, Kipps, Thomas J, Eichhorst, Barbara, Owen, Carolyn J, Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Thadani-Mulero, Maria, Lefebure, Marcus, Jiang, Yanwen, Millen, Rosemary, Boyer, Michelle, Seymour, John F
Publicado 2023

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

por Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D’Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, Kater, Arnon P.
Publicado 2022

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

por Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F.
Publicado 2020

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

por Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., Mato, Anthony R.
Publicado 2022